ADVENTRX Pharmaceuticals to Webcast Presentation at CIBC World Markets Annual Biotechnology & Specialty

ADVENTRX Pharmaceuticals to Webcast Presentation at CIBC World
Markets Annual Biotechnology & Specialty 


SAN DIEGO, April 26  /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals 
(BULLETIN BOARD: AVRX)  will webcast its presentation at the CIBC World Markets
Annual Biotechnology and Specialty Pharmaceuticals Conference, on Tuesday,
April 27 at 9:00 am EDT.  Nicholas Jon Virca, President and CEO, will provide
an update on the latest Company developments.

Interested parties may access the live webcast and replay it by visiting the
ADVENTRX website at http://www.adventrx.com/.  It is suggested that
participants access the webcast 15 minutes before the start of the live
webcast.  The webcast replay will be archived on the News and Events page in
the Investors section of ADVENTRX's web site until May 28, 2004.

About ADVENTRX

ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development
company whose business strategy is to commercialize leading edge medical
research through licensing agreements with prominent universities and research
institutions. The Company focuses on cancer and antiviral research to launch
products that either extend the usefulness of current therapies or replace
marginal therapies with new approaches to treatment. More information on
ADVENTRX and BlockAide/CR can be found on the Company's website at
http://www.adventrx.com/.

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Such statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug development
process, the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the United States Food and
Drug Administration. The Company undertakes no obligation to release publicly
any revisions, which may be made to reflect events or circumstances after the
date hereof.

   Contacts:
   The Ruth Group
   Investors:  Stephanie Carrington
   646-536-7017
   Media:  Cynthia Isaac, Ph.D.
   646-536-7028


DATASOURCE: ADVENTRX Pharmaceuticals



CONTACT:  Investors - Stephanie Carrington, [phone], or Media -

Cynthia Isaac, Ph.D., [phone], both of The Ruth Group, for ADVENTRX

Pharmaceuticals



Web site:  http://www.adventrx.com/ 

Copyright